Stock Fundamentals

Company Information

Company Name
Atea Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US04683R1068
CIK: 0001593899
CUSIP: 04683R106
Currency: USD
Full Time Employees: 55
Phone: 857 284 8891
Fiscal Year End: December
IPO Date: Oct 30, 2020
Description:

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Address:

225 Franklin Street, Boston, MA, United States, 02110

Directors & Officers

Name Title Year Born
Dr. Jean-Pierre Sommadossi Ph.D. Founder, Chairman, CEO & President 1956
Ms. Andrea J. Corcoran J.D. CFO, Executive VP of Legal & Secretary 1962
Mr. John F. Vavricka Chief Commercial Officer 1963
Dr. Janet M. J. Hammond M.D., Ph.D. Chief Development Officer 1960
Dr. Maria Arantxa Horga M.D. Chief Medical Officer 1968
Mr. Wayne Foster CPA Executive VP of Finance & Chief Accounting Officer 1969
Ms. Jonae R. Barnes Senior Vice President of Investor Relations & Corporate Communications NA
Mr. Adel Moussa Ph.D. Executive Vice President of Chemistry NA
Mr. Xiao-Jian Zhou Ph.D. Executive Vice President of Early Stage Development NA
Mr. Keith Pietropaolo Executive VP of Clinical Sciences & Project Management NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 10, 2024 Franklin M Berger N/A Sale 359.61K $2.85 $1.02M
Sep 19, 2024 Jean-Pierre Sommadossi N/A Sale 1.84K $4.00 $7.36K
Sep 17, 2024 Jean-Pierre Sommadossi N/A Sale 33.94K $4.05 $137.46K
Jun 20, 2024 Bruce Polsky N/A Sale 17.54K $3.49 $61.23K
Jun 05, 2024 Jean-Pierre Sommadossi N/A Sale 1.01K $4.00 $4.02K
Feb 01, 2024 Andrea Corcoran N/A Sale 15.84K $3.84 $60.84K
Feb 01, 2024 Jean-Pierre Sommadossi N/A Sale 56.91K $3.85 $219.10K
Feb 01, 2024 Wayne Foster N/A Sale 12.48K $3.84 $47.91K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 11.95M Mar 31, 2026 14.93% $0.00 23.47%
BlackRock Inc 8.44M Mar 31, 2026 10.54% $0.00 -0.66%
BML Capital Management LLC 7.06M Mar 31, 2026 8.82% $24.38 -5.76%
TANG CAPITAL MANAGEMENT LLC 4.81M Mar 31, 2026 6.02% $1.32 0.00%
Vanguard Group Inc 4.23M Dec 31, 2025 5.28% $0.00 -10.24%
Bain Capital Life Sciences Investors, LLC 2.36M Mar 31, 2026 2.95% $1.15 -5.03%
Two Sigma Investments LLC 1.86M Mar 31, 2026 2.33% $0.01 150.08%
Geode Capital Management, LLC 1.75M Mar 31, 2026 2.18% $0.00 -5.07%
State Street Corp 1.69M Mar 31, 2026 2.12% $0.00 -5.03%
Acadian Asset Management LLC 1.58M Mar 31, 2026 1.98% $0.01 10,689.48%
Dimensional Fund Advisors, Inc. 1.26M Mar 31, 2026 1.57% $0.00 -8.62%
Rosalind Advisors, Inc. 1.17M Mar 31, 2026 1.46% $2.53 0.00%
Renaissance Technologies Corp 1.17M Mar 31, 2026 1.46% $0.01 -1.86%
Two Sigma Advisers, LLC 1.06M Dec 31, 2025 1.32% $0.01 33.09%
JPMorgan Chase & Co 940.16K Mar 31, 2026 1.17% $0.00 -30.27%
Morgan Stanley - Brokerage Accounts 731.02K Mar 31, 2026 0.91% $0.00 11.42%
Charles Schwab Investment Management Inc 596.71K Mar 31, 2026 0.75% $0.00 -1.82%
The Goldman Sachs Group Inc 588.46K Mar 31, 2026 0.74% $0.00 24.54%
Northern Trust Corp 585.03K Mar 31, 2026 0.73% $0.00 4.43%
Jane Street Group LLC 418.30K Mar 31, 2026 0.52% $0.00 66.85%

Shares Statistics

Shares Outstanding: 80.03M
Shares Float: 60.23M
% Insiders: 1,340.00%
% Institutions: 8,014.90%
Short % Float: 12.24%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 6.54M 8.17% ▲ 0.47% Mar 31, 2026
2 Fidelity Growth Company Fund 3.05M 3.82% ▲ 19.17% Mar 31, 2026
3 Vanguard Total Stock Mkt Idx Inv 2.37M 2.96% ▲ 0.00% Apr 30, 2026
4 iShares Russell 2000 ETF 1.66M 2.07% ▲ 0.85% Apr 30, 2026
5 Fidelity Growth Company K6 1.23M 1.53% ▲ 0.12% Mar 31, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 814.77K 1.02% ▲ 0.71% Apr 30, 2026
7 Fidelity Series Growth Company 728.82K 0.91% ▲ 21.21% Mar 31, 2026
8 Fidelity Small Cap Index 692.66K 0.87% ▲ 0.41% Feb 28, 2026
9 BlackRock Advantage Small Cap Core Instl 613.37K 0.77% ▲ 0.00% Apr 30, 2026
10 iShares Russell 2000 Value ETF 606.65K 0.76% ▲ 0.54% Apr 30, 2026

Valuation Metrics

Enterprise Value: $94.75M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $341.72M
EBITDA: $-189.18M
Book Value: $2.92
Earnings/Share: $-2.11
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -33.52%
ROE (TTM): -52.58%
Revenue (TTM): $192.18M
Revenue/Share (TTM): $2.31
Earnings Growth (YOY): 264.10%
Revenue Growth (YOY): 295.20%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 7.82x 0.00x 0.13x N/A 0.00x
2024-12-31 24.85x 0.00x 0.06x N/A -0.01x
2023-12-31 18.24x 0.00x 0.07x N/A -0.01x
2022-12-31 35.77x 0.00x 0.04x -11.72x -0.01x
2021-12-31 13.58x 0.00x 0.08x 571.81x 0.00x
2020-12-31 2.73x 0.00x 0.37x -132.89x 0.00x
2019-12-31 9.00x 0.00x 3.25x N/A -0.01x
2018-12-31 19.71x 0.01x 2.04x N/A 0.02x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AVIR.US!